SAN JOSE, Calif., June 17 /PRNewswire-FirstCall/ -- Oclaro, Inc. (Nasdaq: OCLR) has announced the shipment of its 200,000th Fluorescence Filter for biomedical and analytical instrumentation markets. Oclaro filters are used by leading companies in a wide range of biomedical and analytical applications, including clinical diagnostics, drug discovery, gene quantification, blood analysis, and disease detection. The latest offerings from the Oclaro filter portfolio are on display at LASER World of Photonics 2009 in Munich.
Oclaro Clarity(TM) Filters utilise proprietary AED (Advanced Energetic Deposition) coating technology to produce high performance band pass filters, dichroic mirrors, and laser beam combiners. The AED technology facilitates an environmentally stable hard coating that offers superb resistance, high transmission, and high out-of-band blocking. The state of the art Oclaro automated production facilities enable repeatability and high yield at large volumes, ensuring cost effective manufacturing and value for our customers.
"Oclaro Fluorescence Filters are based on proven telecom technology boasting zero failures in over 65 billion recorded hours of operation," said Yves LeMaitre, EVP and General Manager of the Oclaro Advanced Photonic Solutions (APS) division. "We have been manufacturing Clarity Fluorescence Filters for the biomedical market for over five years and have the expertise to deliver quality, innovative products to this demanding and dynamic market."
The APS division leverages the Oclaro telecom expertise and channels it into biomedical and industrial applications. The Clarity fluorescence filter is a prime example of bringing the best of telecom technology manufacturing into biomedical applications, which represents a strategic focus for the APS division of Oclaro.
|SOURCE Oclaro, Inc.|
Copyright©2009 PR Newswire.
All rights reserved